On Friday, Shares of General Growth Properties Inc (NYSE:GGP), gained 0.14% to $27.87.
Grammy-Nominated Sony Music Recording Artist, Jordin Sparks, declared an exclusive marketing partnership with General Growth Properties, Inc. (GGP) to promote her highly anticipated third album, Right Here Right Now releasing on August 21, 2015. The partnership comprises a national sweepstakes, live-stream performance event, a series of exclusive content releases, pop-up appearances and consumer engagement both online and in the malls.
Sparks will make appearances at four GGP malls, giving shoppers an exciting opportunity for an in-person meet-and-greet and purchase download cards of her new album.
At the Fashion Show Mall appearance in Las Vegas, Sparks will conduct a special performance, featuring songs from Right Here Right Now in addition to some of her biggest hits, counting, “No Air” and “One Step at a Time.” The performance will be live-streamed online and broadcast in GGP malls via digital video screens the next day, Sunday, August 16. The partnership also comprises a national sweepstakes that gives one lucky fan a once-in-a- lifetime trip to Los Angeles to get VIP treatment at Glendale Galleria, a $1000 shopping spree and a fun-filled afternoon with Jordin at a surprise destination.
General Growth Properties, Inc is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It engages in owning, managing, leasing, and redeveloping high-quality regional malls. General Growth Properties, Inc is based in Chicago, Illinois.
Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO), declined -7.14% to $19.25, during its last trading session.
Halozyme Therapeutics declared the appointment of Jeffrey W. Henderson to its board of directors. Henderson brings nearly 30 years of financial, commercial, and pharmaceutical industry expertise to the board, most recently serving for almost 10 years as chief financial officer of $100-billion health care products and services company, Cardinal Health.
“We are delighted to appoint an industry executive of Jeff’s caliber to the Halozyme board,” said Dr. Helen Torley, president and chief executive officer. “Jeff brings great depth from his business experience in strategy, finance, M&A and commercial operations that will complement our board’s expertise as we grow the company and prepare for the potential commercialization of our investigational new oncology drug, PEGPH20.”
Henderson served as CFO of Cardinal Health from 2005 until late last year, playing a key role in the company’s growth and transformation. During his tenure, the company attained more than 30 companies, spun-off or sold multi-billion-dollar businesses and expanded into new geographies and market segments. In addition to his financial responsibilities, Henderson also managed commercial operations in China and Canada.
Preceding to Cardinal Health, Henderson was president and general manager of Eli Lilly Canada Inc. and vice president and corporate controller of Eli Lilly & Co. He joined Lilly in 1998 as vice president and corporate treasurer. His preceding experience comprised of 10 years at General Motors Corp., where he served executive and managerial posts in Great Britain, Singapore, New York and Canada. He received his Bachelor of Science degree in electrical engineering from Kettering University, Flint, Mich., and his Master of Business Administration degree from Harvard Graduate School of Business Administration. Henderson is a native of St. Catharines, Ontario, Canada.
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit.
At the end of Friday’s trade, Shares of UnitedHealth Group Inc (NYSE:UNH), gained 0.41% to $121.02.
Expectant mothers who enroll in UnitedHealthcare Community Plan’s Baby Blocks interactive incentive program receive better pre- and postnatal care, keep healthy-baby appointments, and maintain healthy behaviors through their pregnancies, in addition to deliver healthy babies.
Baby Blocks assists manage doctor visits and other baby care during pregnancy and the first two years of their baby’s life. The interactive tool is accessible to women covered by UnitedHealthcare Community Plan in 14 states, counting Kansas. Expectant moms receive incentives for concluding prenatal, postpartum, and healthy-baby appointments. Users can access Baby Blocks via the app on their iPhones and Android smartphones.
In Kansas, the infant mortality rate is more than 6 per 1,000 live births, ranking the state 25th, according to United Health Foundation’s 2014 America’s Heath Rankings report. And more than 7 percent of babies weigh less than 2,500 grams (5 pounds, 8 ounces). Baby Blocks can assist enhance safe and healthy pregnancies and deliveries. Since its launch less than a year ago in Kansas, more than 54 percent of eligible women have enrolled, and 1,487 babies have been born.
UnitedHealth Group Incorporated operates as a diversified health and well-being company in the United States. The company’s UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; and health care coverage, and health and well-being services to individuals aged 50 and older addressing their needs for preventive and acute health care services.
Finally, Biogen Inc (NASDAQ:BIIB), ended its last trade with -0.41% loss, and closed at $312.61.
New clinical data support the long-term safety and efficacy of ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in people with severe hemophilia B treated for up to two years, Biogen (BIIB) declared recently. Participants in the Phase 3, open-label extension study, B-YOND, maintained low bleeding rates with one to two week prophylaxis regimens, according to data from an interim analysis. Investigators presented these interim results for the first time at the 67th Annual Meeting for the National Hemophilia Foundation (NHF) in Dallas.
B-YOND is a multi-year study for people with severe hemophilia B who accomplished the Phase 3 pivotal B-LONG or Kids B-LONG studies. In this interim analysis, the median time on ALPROLIX during B-YOND was 27.6 months for adults and adolescents (n=93), and 47.7 weeks for children under age 12 (n=23). The study’s primary endpoint is inhibitor development, and no inhibitors have been stated to-date. There were three prophylactic dosing options for adult, adolescent, and pediatric participants in the B-YOND trial – weekly, individualized, and modified prophylaxis. An episodic treatment arm was also accessible for adult and adolescent patients.
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
